KCA
Search
- Page Path
- HOME > Search
Original Articles
- Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer
- Dong-Soo Lee, Yeon-Sil Kim, Jin-Hyoung Kang, Sang-Nam Lee, Young-Kyoun Kim, Myung-Im Ahn, Dae-Hee Han, Ie-Ryung Yoo, Young-Pil Wang, Jae-Gil Park, Sei-Chul Yoon, Hong-Seok Jang, Byung-Oak Choi
- Cancer Res Treat. 2011;43(1):32-41. Published online March 31, 2011
- DOI: https://doi.org/10.4143/crt.2011.43.1.32
-
Abstract
PDF
PubReader
ePub - PURPOSE
To evaluate treatment outcomes and prognostic factors in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation.
MATERIALS AND METHODS
From January 2005 to June 2009, 51 patients were treated with concurrent chemoradiation for 3 different aims: locally advanced stage III, locally recurrent disease, and postoperative gross residual NSCLC. Median age was 63 years. Distribution of stages by the 6th edition of American Joint Committee on Cancer (AJCC) was as follows: IIIA (37.3%), IIIB (56.9%). Chemotherapy was administered every week concurrently with radiation using one of the following regimens: paclitaxel (60 mg/m2), docetaxel+cisplatin (20 mg/m2+20 mg/m2), cisplatin (30 mg/m2). Total radiation dose was 16-66.4 Gy (median, 59.4 Gy).
RESULTS
Median follow-up duration was 40.8 months. The overall response rate was 84.3% with 23 complete responses. The median survival duration for the overall patient group was 17.6 months. The 3-year survival rate was 17.8%. A total of 21 patients had recurrent disease at the following sites: loco-regional sites (23.6%), distant organs (27.5%). In the multivariate analysis of the overall patient group, a clinical tumor response (p=0.002) was the only significant prognostic factor for overall survival (OS). In the multivariate analysis of the definitive chemoradiation arm, the use of consolidation chemotherapy (p=0.022), biologically equivalent dose (BED)10 (p=0.007), and a clinical tumor response (p=0.030) were the significant prognostic factors for OS.The median survival duration of the locally recurrent group and the postoperative gross residual group were 26.4 and 23.9 months, respectively.
CONCLUSION
Our study demonstrated that clinical tumor response was significantly associated with OS in the overall patient group. Further investigations regarding the optimal radiation dose in the definitive chemoradiation and the optimal treatment scheme in locally recurrent NSCLC would be required. -
Citations
Citations to this article as recorded by
- A scoping review on population-centered indicators for cancer care continuum
Vasuki Rajaguru, Jieun Jang, Jeoung A. Kwon, Jae Hyun Kim, Jaeyong Shin, Mison Chun
Frontiers in Public Health.2022;[Epub] CrossRef - Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
Lipin Liu, Nan Bi, Zhe Ji, Junling Li, Jingbo Wang, Xiaozhen Wang, Zhouguang Hui, Jima Lv, Jun Liang, Zongmei Zhou, Yan Wang, Weibo Yin, Luhua Wang
BMC Cancer.2015;[Epub] CrossRef - Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer
Jian L. Campian, Xiaobu Ye, Malcolm Brock, Stuart A. Grossman
Cancer Investigation.2013; 31(3): 183. CrossRef - Does Pneumonectomy Have a Role in the Treatment of Stage IIIA Non-Small Cell Lung Cancer?
Asad A. Shah, Mathias Worni, Christopher R. Kelsey, Mark W. Onaitis, Thomas A. D'Amico, Mark F. Berry
The Annals of Thoracic Surgery.2013; 95(5): 1700. CrossRef - Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
Gangjun Du, Yingming Yang, Yaping Zhang, Ting Sun, Weijie Liu, Yingying Wang, Jiahuan Li, Houyun Zhang
Cancer Chemotherapy and Pharmacology.2013; 71(4): 893. CrossRef
- A scoping review on population-centered indicators for cancer care continuum
- 11,256 View
- 67 Download
- 5 Crossref
- 5-Fluorouracil, Leucovorin ( FL ) Combination Chemotherapy in Advanced or Recurrent Colo - rectal Cancer
- Jeong Hwan Cho, Hyuk Chan Kwon, Hyo Jin Kim
- J Korean Cancer Assoc. 1999;31(5):1003-1010.
-
Abstract
PDF
- PURPOSE
We studied the effectiveness and toxicities of 5-fluorouracil+leucovorin, combination chemotherapy in advanced or recurred colo-rectal cancer patients, who didn't have previous chemotherapy and enrolled from August 1993 to July 1998.
MATERIALS AND METHODS
All patients were treated with leucovorin followed by 5-fluorouracil for 5 consecutive days every 4 weeks. Among 43 patients who were enrolled, 40 patients received treatment at least 2 courses, and they were evaluable. Male to female ratio was 21 to 19. In serum CEA level, 27 patients were greater than 5 ng/ml and 13 were less than 5 ng/ml. And primary site was colon in 21 patients and rectum in 19 patients.
RESULTS
The complete response rate was 7,5% and the partial response rate was 25%. The median survival duration was 14.7 months, the median response duration was 16.0 months, and median time to progression was 7.3 months. In the analysis of response, survival duration, time to progression according to various characteristics of patients, serum CEA level and liver involvement were revealed significant difference in survival duration, time to progression (p=0.0122, 00350 & 0.0202, 0.0123) on univariate analysis, but no significant difference on multivariates. Hematologic and non-hematologic toxicities were mild and tolerable.
CONCLUSION
This study indicates that the combination of 5-fluorouracil (370 mg/m) and leucovorin (20 mg/m) is effective and tolerable regimen in advanced or recurred colo-rectal cancer patients without previous chemotherapy.
- 4,666 View
- 46 Download
First
Prev
